04/07/2022 New library of resources for translational medicine research on rare diseases 04/07/2022 The European Joint Programme on Rare Diseases (EJP RD) announces the release of the Innovation Management Toolbox (IMT), a tool created to provide self-help resources specific to the needs of researchers in this type of pathologies. The European Joint Programme on Rare Diseases (EJP RD), in which VHIR participates, announces the release of the Innovation Management Toolbox (IMT), a reference tool to assist researchers in rare diseases in their translational medicine projects. The Innovation Management Toolbox is a library of translational medicine resources on rare diseases. It is free to use and has been designed to offer specific self-help resources for researchers' needs. The different resources have undergone a review process to improve their searchability, and in general the database remains actively maintained, i.e. it will be updated as new technologies, guidelines and services for this scientific community become available. The IMT aims to help researchers navigate independently the complexities of translational drug development, as well as to give a clear overview of the services and funding opportunities that are available at the European level to carry out their projects. The ultimate impact of this tool is to reduce uncertainty and inefficiency in the academic translational research process, resulting in faster development and more patient-centered research outcomes. For more info, visit the IMT website where you will find a video tutorial on how it works. European Joint Programme on Rare Diseases (EJP RD) The Joint European Program for Rare Diseases (EJP RD) is made up of more than 130 institutions from 35 countries with the aim of creating an ecosystem of collaboration in research, care and medical innovation. Because of its low frequency, the area of rare diseases is particularly likely to benefit from coordination between centers at European and international level. Thus, this program hopes to lead to an efficient use of data and resources and faster scientific progress for the benefit of patients with this type of pathology. Twitter LinkedIn Facebook Whatsapp